Background-Hemoglobin A1c (HbA1c) is the standard measure to monitor glucose control in diabetes mellitus and is a marker of future cardiovascular risk. Fructosamine and glycated albumin are markers of short-term glycemic control, but their associations with cardiovascular outcomes are uncharacterized. Methods and Results-We measured glycated albumin and fructosamine in 11 104 participants with and without diabetes in the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990 to 1992 (baseline). We evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, ischemic stroke, heart failure, and mortality. We compared associations with those observed for HbA1c. During two decades of follow-up there were 1096 new cases of coronary heart disease, 605 of ischemic stroke, 1432 of heart failure, and 2860 deaths. Elevated baseline concentrations of fructosamine and glycated albumin were significantly associated with each of the outcomes even after adjustment for traditional cardiovascular risk factors, with especially strong associations in persons with diabetes mellitus. Associations were of similar magnitude to those observed for HbA1c and-as has been previously observed for HbA1c-the associations tended to be J-shaped, with an elevation of risk at the lowest levels of each biomarker.
H emoglobin A1c (HbA1c) reflects exposure to glucose concentrations over an approximate 2-to 3-month period and has long been the standard measure used clinically to monitor glycemic control in persons with diabetes mellitus. HbA1c is also now recommended for use in diagnosis of diabetes mellitus. Nonetheless, HbA1c has important limitations: it does not change rapidly in response to changes in treatment, and a number of conditions affect the validity of the test result (eg, anemia, altered red cell lifespan, transfusion, kidney disease, liver disease, and abnormal forms of hemoglobin).
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Fructosamine (glucose bound to circulating serum proteins, mainly albumins but also globulins and other proteins) and glycated albumin (glucose bound specifically to albumin) reflect glycemic control over the previous 2 to 4 weeks, reflecting the turnover of plasma proteins. Both fructosamine and glycated albumin can be measured in serum or plasma and may be useful for assessment of hyperglycemia in settings where HbA1c testing is problematic or not available.
There is growing interest and use of nontraditional biomarkers of hyperglycemia such as fructosamine and glycated albumin but limited data linking these tests to long-term outcomes. We have previously shown that fructosamine and glycated albumin are strongly associated with microvascular complications and may add prognostic information to HbA1c in the general population. 1 Recent statements from professional diabetes and laboratory organizations have suggested the utility of these biomarkers, but have cited their unclear prognostic value as a barrier to their use and interpretation. [2] [3] [4] [5] [6] The primary objective of this study was to characterize the associations of fructosamine and glycated albumin with risk of coronary heart disease, ischemic stroke, heart failure, and total mortality in the community. We evaluated associations overall and compared associations among persons with and without a history of diabetes mellitus. A secondary objective was to compare risk factor associations for elevated levels of fructosamine and glycated albumin to HbA1c in persons without a history of diagnosed diabetes mellitus.
Methods

Study Population
The Atherosclerosis Risk in Communities (ARIC) Study is a prospective cohort of originally 15 792 persons from 4 US communities: Forsyth, North Carolina; Jackson, Mississippi; suburban Minneapolis, Minnesota; and Washington County, Maryland. The first examination took place from 1987 to 1989, with 3 follow-up visits occurring approximately every 3 years. A fifth examination was completed from 2011 to 2013. The second examination took place from 1990 to 1992, was attended by 14 348 participants, and is the baseline for the present study. For the purposes of this study, we excluded persons who had a history of cardiovascular disease at baseline, were missing variables of interest, or who were fasting for fewer than 8 hours at the time of the examination. The final study sample included 11 104 participants (762 with a history of diabetes mellitus).
Institutional review boards at all institutions reviewed the study, and written informed consent was obtained from all participants.
Measurement of Fructosamine and Glycated Albumin
Fructosamine (Roche Diagnostics Corp, Indianapolis, IN) and glycated albumin (Lucia GA-L, Asahi Kasei Corp, Tokyo, Japan) were measured in 2012 to 2013 from serum samples, using a Roche Modular P800 system. Samples had been stored at −70°C since collection during the baseline examination in 1990 to 1992. For fructosamine, the interassay coefficients of variation were 3.2% at a concentration of 212.6 μmol/L and 2.5% at a concentration of 856.7 μmol/L. For glycated albumin, the interassay coefficients of variation were 2.3% at a concentration of 1.579 g/dL and 2.8% at a concentration of 0.426 g/dL. Previous studies have demonstrated the stability of these analytes in long-term stored samples.
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Ascertainment of Incident Cardiovascular Events
The ascertainment of cardiovascular events and deaths has been detailed previously. [10] [11] [12] Briefly, all hospitalizations are reported annually or semiannually (since 2012) by participants or their proxies and also identified by community-wide surveillance of local hospital discharge indices. Trained personnel abstract hospital records related to possible cardiovascular events. Deaths were also ascertained from state records and linkage to the National Death Index. Silent myocardial infarctions were identified from electrocardiograms conducted at the study examinations. We defined incident coronary heart disease events as the first occurrence of a validated definite or probable hospitalized myocardial infarction, a death from coronary heart disease, or electrocardiographic evidence of a silent myocardial infarction (during the study visits). We also examined definite or probable ischemic stroke. Heart failure was defined by a hospitalization with an International Classification of Diseases (ICD)-9 code of 428 or death with an underlying cause of ICD-9 428 or ICD-10 I50. 13 Participants who had a noncardiac death were censored at the time of death in analyses of incident cardiovascular events.
Other Variables of Interest
All measurements were conducted at baseline unless stated otherwise. Diagnosed diabetes mellitus was defined on the basis of a self-reported physician diagnosis or current use of diabetes mellitus drugs. Serum glucose was measured using the hexokinase method. HbA1c was measured from stored whole blood samples using high performance liquid chromatography instruments standardized to the Diabetes Control and Complications Trial assay.
14 Body mass index, blood pressure, and lipid concentrations were assessed using published methods. [15] [16] [17] [18] [19] [20] Hypertension was defined as a systolic blood pressure of 140 mm Hg or higher, or diastolic blood pressure of 90 mm Hg or higher from the mean of the second and third readings at the examination; or the current use of hypertension medication. Participants self-reported their educational level (at visit 1 only), alcohol use, and smoking status.
Statistical Analyses
We calculated summary statistics to characterize the baseline population overall and within the populations of persons with and without diagnosed diabetes mellitus stratified by concentrations of fructosamine and glycated albumin at baseline. Because there are no established clinical cut-points for either fructosamine or glycated albumin, we used cut-points pegged to clinical categories of HbA1c. We divided the population of persons without diagnosed diabetes into three groups defined by the 70th and 96th percentiles of each biomarker (≤70th, 71st to 96th, and higher than the 96th percentile). These cut-points were used for equivalence to the clinical (diagnostic) values of HbA1c 5.7% (the 70th percentile) and 6.5% (the 96th percentile). In persons with diagnosed diabetes mellitus, we divided the population into two groups, above and below the 38th percentile (equivalent to an HbA1c value of 7%). In persons without diagnosed diabetes mellitus at baseline, we used multivariable logistic regression models to compare associations of traditional diabetes mellitus risk factors with elevated values of fructosamine, glycated albumin, and HbA1c, where elevated was defined as values above the 96th percentile (equivalent to an HbA1c value of 6.5%).
Adjusted hazard ratios and their corresponding confidence intervals were estimated using Cox proportional hazards models. Our main analyses were conducted with fructosamine, glycated albumin, and HbA1c modeled using diabetes mellitus-specific categories using the cut points as described above. P values for trends across all the categories were calculated by modeling the category medians as a continuous variable. The 2 core models were specified as follows: Model 1 was adjusted for age, sex, body mass index, body mass index 2 , race-field center; Model 2 was adjusted for all variables in Model 1 plus lowdensity lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, waist-to-hip ratio, systolic blood pressure, blood pressure-lowering medication use, parental history of diabetes mellitus, education, drinking status, smoking status, and physical activity level. We also conducted analyses additionally adjusting for all variables in Model 2 plus HbA1c. We verified that the proportional hazards assumption was met using log-log plots.
To characterize the shape and compare the continuous associations of fructosamine, glycated albumin, and HbA1c with each of the outcomes in the overall population we fit linear and restricted cubic splines with 4 knots placed at the 5th, 35th, 65th, and 95th percentiles. 21 Model discrimination with the addition of fructosamine, glycated albumin, or HbA1c to our core models (Model 1 and Model 2) was assessed using Harrel's C statistic. 22 We also calculated the relative integrated discrimination improvement (IDI) statistic 23, 24 to assess the overall improvement in risk classification for the addition of fructosamine, glycated albumin, or HbA1c to the models. We conducted sensitivity analyses stratified by diabetes mellitus status. All reported P values are 2-sided, with P<0.05 indicating statistical significance. Statistical analyses were done using Stata/SE Version 13.1 (StataCorp, College Station, TX).
Results
Persons with higher fructosamine or glycated albumin values at baseline were more likely to be older, female, black, obese, hypertensive, and have a parental history of diabetes mellitus as compared with persons with lower values of fructosamine or glycated albumin ( Table 1 ). The Pearson correlations of HbA1c with fructosamine or glycated albumin were high in the overall population: 0.81 and 0.85, respectively. Correlations were lower when the population was limited to those persons without diagnosed diabetes (Table I in the online-only Data Supplement).
In persons without a diagnosis of diabetes, we conducted cross-sectional multivariable analyses to examine the independent correlates of elevated fructosamine or glycated albumin (ie, values above the 96th percentile). These associations were compared to those for elevated HbA1c (ie, values above the 96th percentile, ≥6.5%) ( Table 2) . We found that risk factor associations for elevated fructosamine or glycated albumin were, in general, relatively similar to risk factor associations observed for elevated HbA1c. In particular, older age, black race/ethnicity, hypertension, parental history of diabetes mellitus, and elevated liver markers (ALT, AST, or GGT) were consistently associated with elevated values of all 3 biomarkers of hyperglycemia. Current alcohol consumption was associated with lower (nonelevated) values of each biomarker. Low highdensity lipoprotein cholesterol and high triglycerides were associated with elevated biomarker levels, but these results were more robust for elevated HbA1c as compared with fructosamine or glycated albumin. Current smoking status was not associated with HbA1c but was associated with lower values of fructosamine or glycated albumin. Low kidney function (estimated glomerular filtration rate <60 mL/min/1.73m 2 ) was significantly associated with elevated fructosamine, but the positive associations of eGFR with elevated glycated albumin and HbA1c were of smaller magnitude and not statistically significant. Anemia was positively associated with elevated glycated albumin. Substantial differences in associations were observed for body mass index and also C-reactive protein.
Higher body mass index and C-reactive protein were strongly *Estimates are mean (standard deviation) or %. Fructosamine and glycated albumin were divided into categories defined by the ≤70th, 71th-96th, >96th percentiles in persons without diagnosed diabetes mellitus and by the ≤38th, >38th percentiles in persons with diagnosed diabetes mellitus. These percentiles correspond to hemoglobin A1c categories of <5.7%, 5.7-6.4%, and >6.4% in persons without diagnosed diabetes mellitus, and hemoglobin A1c categories of <7%, ≥7% in persons with diagnosed diabetes mellitus.
by guest on May 1, 2017 http://circ.ahajournals.org/ Downloaded from associated with elevated HbA1c but not with elevated fructosamine or glycated albumin. In additional analyses, there was evidence of nonlinearity and Spearman correlations revealed modest inverse correlations of body mass index with glycated albumin (Spearman r = -0.15) and fructosamine (Spearman r = -0.14) in persons without diagnosed diabetes mellitus. This is in contrast to the positive correlation between HbA1c and body mass index (Spearman r = 0.26).
During approximately 2 decades of follow-up there were 1096 new cases of coronary heart disease, 605 of ischemic stroke, 1432 of heart failure, and 2860 deaths. In persons both with and without diagnosed diabetes mellitus, there was a higher risk of coronary heart disease, stroke, health failure, and death among persons with elevated fructosamine or elevated glycated albumin (Table 3 and Figures 1 and 2) . In general, the associations were of similar magnitude to the associations observed for HbA1c (Figures 1 and 2 ), except for stroke, which appeared to have a stronger association with HbA1c ( Figure 1D-1F ). There was also some evidence for a higher risk of events at very low values of fructosamine and glycated albumin, especially for heart failure and all-cause mortality (Figure 2 ), but some of the confidence intervals in the very low range were wide and overlapped the null value of 1. Similar results were also obtained when fructosamine or glycated albumin were modeled using linear splines ( Figure I in the online-only Data Supplement). When we modeled the associations separately for persons with or without diagnosed diabetes mellitus, we observed largely similar results and with generally more linear risk associations Low HDL: high-density lipoprotein cholesterol <40 mg/dL for men, <50 mg/dL for women. Anemia: hemoglobin <13 g/dL for men, <12 g/dL for women. High AST, ALT, and GGT are based on sex-specific 95th percentiles: High AST: ≥32 U/L for men, ≥28 U/L for women; High ALT: ≥29 U/L for men, ≥23 U/L for women; High GGT: ≥70 U/L for men, ≥52 U/L for women.
*Adjusted for age, race-center, and sex. †P value <0.05. . The associations of fructosamine and glycated albumin with events were attenuated but remained statistically significant even after adjustment for HbA1c, with the exception of ischemic stroke (Table II in the online-only Data Supplement). Table 4 presents the relative IDI and C-statistics comparing models with and without the different glycemic markers. We observed similar and statistically significant improvements in the C statistics when fructosamine, glycated albumin, or HbA1c were added to Model 1 or Model 2. The IDI statistics were highly consistent with the C statistic results.
Discussion
The acceptance of new measures of hyperglycemia is partly dependent on establishing their association with long-term outcomes. Furthermore, the comparison of risk factor associations for elevations in nontraditional versus traditional biomarkers of hyperglycemia is important for the interpretation of these biomarkers in the general population and the clinic. Previous studies have demonstrated strong associations between fructosamine and glycated albumin with microvascular conditions, 1, 25, 26 with associations of similar magnitude to those observed for HbA1c. Data on risk associations using modern assays of fructosamine and glycated albumin with cardiovascular disease are sparse, and previous studies have been limited by cross-sectional designs or prospective studies with small numbers of cardiovascular events. 25, 26 In the present study, we found that both fructosamine and glycated albumin were associated with coronary heart disease, ischemic stroke, heart failure, and death, with patterns of association similar to those observed for HbA1c. Even after adjustment for HbA1c, fructosamine and glycated albumin remained significantly associated with vascular outcomes and death. Indeed, improvements in the C statistic and IDI when fructosamine, glycated albumin, or HbA1c were added to our fully adjusted model were all similar and statistically significant. Our results inform the prognostic value of fructosamine and glycated albumin.
Interestingly, we observed J-shaped associations of fructosamine and glycated albumin with some of the outcomes examined here, particularly mortality. A J-shaped association of HbA1c with risk of vascular end points and mortality has been observed in a number of different populations. [27] [28] [29] [30] [31] Previous studies have suggested that low normal values of HbA1c may be associated Models adjusted for age (years), race-center, sex (male, female), body mass index (kg/m 2 ), body mass index squared, low-density lipoprotein cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL), triglycerides (mg/dL), waist-to-hip ratio, systolic blood pressure (mm Hg), blood pressure-lowering medication use (yes, no), parental history of diabetes mellitus (yes, no), education (less than high school, high school or equivalent, more than high school), drinking status (current, former, never), smoking status (current, former, never), and physical activity index. P values for trends across all the categories were calculated by modeling the category medians as a continuous variable in the model. CI indicates confidence interval; and HR, hazard ratio.
*Fructosamine and glycated albumin were divided into categories defined by the ≤70th, 71st-96th, >96th percentiles in persons without diagnosed diabetes mellitus and by the ≤38th, >38th percentiles with diagnosed diabetes mellitus. These percentiles correspond to hemoglobin A1c categories of <5.7%, 5.7-6.4%, and >6.4% in persons without diagnosed diabetes mellitus, and hemoglobin A1c categories of <7%, ≥7% in persons with diagnosed diabetes mellitus. with an increased risk of cardiovascular disease or death as a result of subclinical illness or possibly liver dysfunction. Indeed, it has been shown that persons with low-normal HbA1c have a high prevalence of elevated liver markers and hepatitis C (11.1% hepatitis C seropositivity in persons with HbA1c <4% compared with ≈2% in the rest of the US adult population) 30 and an elevated risk of hospitalization for liver-related conditions. 32 The elevated risk of cardiovascular disease and death at low-normal values of fructosamine and glycated albumin is consistent with previous studies of HbA1c and deserves further examination. The correlations of HbA1c with fructosamine and glycated albumin in the overall population were high. The lower correlations (especially Spearman correlations) in persons without a history of diabetes mellitus reflect discordance of HbA1c , and hemoglobin A1c (HbA1c; C and F) with incident heart failure and all-cause mortality. *Adjusted HRs are from Cox proportional hazards models. Baseline fructosamine, glycated albumin, and HbA1c were modeled using restricted cubic splines (solid lines) with knots at the 5th, 35th, 65th, and 95th percentiles. Models are centered at the 50th percentile of each marker and are adjusted for age (years), race-center, sex (male, female), low-density lipoprotein cholesterol (mg/dL), highdensity lipoprotein cholesterol (mg/dL), triglycerides (mg/dL), body mass index (kg/m 2 ), body mass index squared, waist-to-hip ratio, mean systolic blood pressure (mm Hg), blood pressure-lowering medication use (yes, no), diabetes mellitus (yes, no), parental history of diabetes mellitus (yes, no), education (less than high school, high school or equivalent, more than high school), drinking status (current, former, never), smoking status (current, former, never), and physical activity index (score). Frequency histograms (gray bars) are shown for each biomarker, and are truncated at the 95th percentile. 95% confidence intervals are shown by the dotted lines. , and hemoglobin A1c (HbA1c; C and F) with incident coronary heart disease and ischemic stroke. *Adjusted HRs are from Cox proportional hazards models. Baseline fructosamine, glycated albumin, and HbA1c were modeled using restricted cubic splines (solid lines) with knots at the 5th, 35th, 65th, and 95th percentiles. Models are centered at the 50th percentile of each marker and are adjusted for age (years), race-center, sex (male, female), low-density lipoprotein cholesterol (mg/dL), highdensity lipoprotein cholesterol (mg/dL), triglycerides (mg/dL), body mass index (kg/m 2 ), body mass index squared, waist-to-hip ratio, mean systolic blood pressure (mm Hg), blood pressure-lowering medication use (yes, no), diabetes mellitus (yes, no), parental history of diabetes mellitus (yes, no), education (less than high school, high school or equivalent, more than high school), drinking status (current, former, never), smoking status (current, former, never), and physical activity index (score). ), body mass index squared. Model 2: Model 1 + low-density lipoprotein cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL), triglycerides (mg/dL), waist-to-hip ratio, systolic blood pressure (mm Hg), blood pressurelowering medication use (yes, no), parental history of diabetes mellitus (yes, no), education (less than high school, high school or equivalent, more than high school), drinking status (current, former, never), smoking status (current, former, never), and physical activity index. Each marker is modeled using cubic splines with 4 knots (at the 5th, 35th, 65th, and 95th percentiles).
by guest on May 1, 2017 http://circ.ahajournals.org/ Downloaded from possible that protein metabolism is altered in obese adults and may be affected by inflammation. C-reactive protein is known to be highly associated with body mass index and is lowered by weight loss. [42] [43] [44] In addition to alterations in protein metabolism, other conditions that may affect the interpretation of fructosamine and glycated albumin test results include liver disease, hyperuricemia, acute illness or infection, and thyroid dysfunction. 25 Nonetheless, the overall similarity of major diabetes mellitus risk factor associations for elevated HbA1c, fructosamine, and glycated albumin is reassuring and suggests that, in general, elevations in fructosamine and glycated albumin are largely being driven by the same pathophysiological processes that act to raise blood glucose concentrations over time.
Important limitations that should be considered when interpreting our results include the single baseline measurements of fructosamine, glycated albumin, and HbA1c. We also did not have contemporaneous 2-hour glucose measurements for comparison. Strengths of the study include the large communitybased sample, active surveillance for cardiovascular events and deaths, and high number of incident events and deaths during the >20 years of follow-up. This study also benefited from the rigorous data collection and measurement of covariates in ARIC, and we implemented an array of statistical models to fully explore possible nonlinear associations of fructosamine and glycated albumin with risk factors and clinical outcomes in our data. We also demonstrated excellent laboratory performance of the fructosamine and glycated albumin assays used here (intra-assays coefficients of variation of ≤3%). Our experience in the laboratory has been that fructosamine and glycated albumin are all highly stable, and we have been able to conduct these tests with high reliability and validity in long-term stored samples in multiple studies. 7, 9, 45, 46 Further, investigators of the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study have demonstrated robust associations of the same glycated albumin assay with outcomes in a type 1 diabetes mellitus population 26 and excellent stability in samples stored for 19 to 23 years. 8 In conclusion, we found that fructosamine and glycated albumin were associated with vascular outcomes and mortality in the community and that these associations were similar to those observed for HbA1c. Our results add to growing evidence for the utility of fructosamine or glycated albumin in settings where HbA1c testing cannot be used or where its interpretation is problematic. 
